【摘要】 目的:评估卡泊芬净治疗恶性血液病合并侵袭性肺曲霉菌(IPA)感染的临床疗效和安全性。方法:2008年1月-2012年12月恶性血液病合并IPA感染患者49例,所有患者均经CT检查和GM试验临床诊断;采用注射用醋酸卡泊芬净进行治疗,根据临床疗效标准,评价卡泊芬净治疗的疗效和安全性。结果:49例患者的治疗总有效率为91.84%(45/49)。卡泊芬净治疗过程中9例发生不良反应,不良反应发生率为18.37%。结论:卡泊芬净有很好的抗真菌活性,是治疗恶性血液病合并肺曲霉菌感染安全有效的药物。更多还原

【Abstract】 Objective: To evaluate the clinical efficacy and safety of caspofungin in treatment of hematological malignancies combined invasive pulmonary aspergillosis(IPA) infection.Methods: 49 hematological malignancies combined IPA infection patients(2008.1-2012.12) that were diagnosed by CT and galactomannan test were treated with caspofungin. The clinical effi cacy and safety of caspofungin were evaluated according to clinical curative effect standard. Results:The total effective rate of 49 patients was 91.84%(45/49) after caspofungin treatment; and the incidence of drug related adverse events was 18.37%(9/49).Conclusions:Caspofungin has good antifungal activity,and it is a safe and effective drug for treating hematological malignancies combined IPA infection.更多还原